UY28101A1 - Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer - Google Patents
Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimerInfo
- Publication number
- UY28101A1 UY28101A1 UY28101A UY28101A UY28101A1 UY 28101 A1 UY28101 A1 UY 28101A1 UY 28101 A UY28101 A UY 28101A UY 28101 A UY28101 A UY 28101A UY 28101 A1 UY28101 A1 UY 28101A1
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- alzheimer
- disease
- useful
- substituted ureas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
La invención brinda compuestos de fórmula I: útiles para el tratamiento de la Enfermedad de Alzheimer y otras enfermedades similares. Los compuestos incluyen inhibidores de la enzima beta-secretasa que son útiles para el tratamiento de la Enfermedad de Alzheimer y otras enfermedades caracterizadas por el depósito de péptido A beta en un mamífero. Los compuestos de la invención son útiles en composiciones farmacéuticas y métodos de tratamiento para reducir la formación de péptido A beta.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42976902P | 2002-11-27 | 2002-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28101A1 true UY28101A1 (es) | 2004-06-30 |
Family
ID=32469374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28101A UY28101A1 (es) | 2002-11-27 | 2003-11-27 | Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer |
Country Status (14)
Country | Link |
---|---|
US (2) | US7351738B2 (es) |
EP (1) | EP1565428A1 (es) |
JP (1) | JP2006508166A (es) |
AR (1) | AR043062A1 (es) |
AU (1) | AU2003293155A1 (es) |
BR (1) | BR0316629A (es) |
CA (1) | CA2507484A1 (es) |
DO (1) | DOP2003000765A (es) |
MX (1) | MXPA05005649A (es) |
PA (1) | PA8589701A1 (es) |
PE (1) | PE20040762A1 (es) |
TW (1) | TW200505828A (es) |
UY (1) | UY28101A1 (es) |
WO (1) | WO2004050609A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
US7291744B2 (en) * | 2003-11-13 | 2007-11-06 | Bristol-Myers Squibb Company | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
JP2007522129A (ja) * | 2004-01-21 | 2007-08-09 | エラン ファーマシューティカルズ,インコーポレイテッド | アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法 |
CA2558249A1 (en) * | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors |
WO2005087714A2 (en) * | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors |
JP2007528400A (ja) | 2004-03-09 | 2007-10-11 | エラン ファーマシューティカルズ,インコーポレイテッド | 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬 |
EP1773758A1 (en) * | 2004-07-09 | 2007-04-18 | Elan Pharmaceuticals, Inc. | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors |
US7385085B2 (en) | 2004-07-09 | 2008-06-10 | Elan Pharmaceuticals, Inc. | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
EP1797052A1 (en) * | 2004-09-17 | 2007-06-20 | Comentis, Inc. | Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof |
CN101142194B (zh) * | 2005-03-14 | 2012-10-10 | 顶点制药有限责任公司 | 吲哚衍生物,组合物及用作β-分泌酶抑制剂的方法 |
JP2008535863A (ja) * | 2005-04-08 | 2008-09-04 | コメンティス,インコーポレーテッド | β−セクレターゼ活性を阻害する化合物およびその使用方法 |
CN101238111A (zh) * | 2005-08-03 | 2008-08-06 | 默克公司 | 用于治疗阿尔茨海默氏病的环缩酮β-分泌酶抑制剂 |
JP5030781B2 (ja) * | 2005-09-05 | 2012-09-19 | 良明 木曽 | βセクレターゼ阻害剤 |
CA2624904A1 (en) * | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors |
WO2007047305A1 (en) | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors |
US7872009B2 (en) * | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
US7745484B2 (en) * | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
US7838676B2 (en) * | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
CA2629402C (en) * | 2005-11-21 | 2011-07-26 | Amgen Inc. | Beta-secretase modulators and methods of use |
US20080277393A1 (en) * | 2007-05-07 | 2008-11-13 | True Charles W | Collapsible, stackable, semi-rigid universal cotainer for hazardous and non-hazardous goods |
CL2008001500A1 (es) | 2007-05-25 | 2008-12-26 | Amgen Inc | Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros. |
EP2167471B1 (en) | 2007-05-25 | 2013-10-16 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
CA2697166A1 (en) * | 2007-07-26 | 2009-01-29 | Comentis, Inc. | Isophthalamide derivatives inhibiting betasecretase activity |
US8163953B2 (en) | 2008-04-18 | 2012-04-24 | University Of Connecticut | Compounds for lysosomal modulation and methods of use |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
JPS6133152A (ja) * | 1984-06-22 | 1986-02-17 | アボツト ラボラトリ−ズ | リ−ニン阻害化合物 |
EP0190891A3 (en) * | 1985-01-31 | 1988-04-20 | Kissei Pharmaceutical Co. Ltd. | Novel amino acid derivatives |
US4665055A (en) * | 1985-06-17 | 1987-05-12 | Merck & Co., Inc. | Peptide renin inhibitors |
US5175281A (en) | 1985-09-12 | 1992-12-29 | The Upjohn Company | Pharmaceutically active pyrimidinylpiperazinylsterioids |
CA1297631C (en) * | 1985-12-23 | 1992-03-17 | Sesha I. Natarajan | Ureido renin inhibitors |
US4864017A (en) | 1986-09-05 | 1989-09-05 | The Upjohn Company | Novel renin inhibiting peptides having a dihyroxyethylene isostere transition state insert |
US5912410A (en) | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
WO1991019810A1 (en) | 1990-06-15 | 1991-12-26 | California Biotechnology Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
ATE296625T1 (de) * | 1990-11-19 | 2005-06-15 | Monsanto Co | Retrovirusprotease inhibitoren |
JP3510244B2 (ja) * | 1991-01-21 | 2004-03-22 | エラン ファーマシューティカルス,インコーポレイテッド | アルツハイマー病に関するテストおよびモデル |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
CA2109326A1 (en) * | 1991-07-02 | 1993-01-03 | Andreas Billich | 4-amino-3-hydroxycarboxylic acid derivatives |
WO1993014200A1 (en) | 1992-01-07 | 1993-07-22 | Tsi Corporation | Transgenic animal models for alzheimer's disease |
US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
CA2140928C (en) * | 1992-08-25 | 2008-01-29 | Michael L. Vazquez | Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
US5578606A (en) * | 1992-10-30 | 1996-11-26 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
CA2174429C (en) * | 1993-10-27 | 2011-08-30 | Lisa C. Mcconlogue | Transgenic animals harboring app allele having swedish mutation |
US5877399A (en) * | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
US5606078A (en) | 1994-04-18 | 1997-02-25 | Ciba-Geigy Corporation | 3,5-Disubstituted tetrahydrofuran-2-ones |
JP2002515004A (ja) * | 1994-07-07 | 2002-05-21 | ファーム−エコ ラボラトリーズ,インコーポレイテッド | アミノ酸誘導ジアミノプロパノール |
EP0702004A2 (de) | 1994-09-15 | 1996-03-20 | Ciba-Geigy Ag | 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative |
EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
US5691372A (en) * | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
JPH11507538A (ja) * | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
US5744346A (en) * | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
JPH09124629A (ja) * | 1995-10-26 | 1997-05-13 | Kissei Pharmaceut Co Ltd | カルバミン酸テトラヒドロフリルエステル誘導体の製造方法 |
EP0948630B1 (en) | 1996-11-20 | 2008-04-23 | Oklahoma Medical Research Foundation | Cloning and characterization of napsin, an aspartic protease |
US6191166B1 (en) * | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
AU5002399A (en) | 1998-07-17 | 2000-02-07 | National Broach And Machine Company | Full form roll finishing technique |
SG113454A1 (en) | 1998-09-24 | 2005-08-29 | Upjohn Co | Alzheimer's disease secretase |
CA2359785A1 (en) | 1999-02-10 | 2000-08-17 | John P. Anderson | .beta.-secretase enzyme compositions and methods |
JP4814427B2 (ja) * | 1999-02-12 | 2011-11-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | アスパルチルプロテアーゼのインヒビター |
WO2000077030A1 (en) | 1999-06-15 | 2000-12-21 | Elan Pharmaceuticals, Inc. | Statine-derived tetrapeptide inhibitors of beta-secretase |
AU782312B2 (en) | 1999-09-23 | 2005-07-21 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
GB0012795D0 (en) * | 2000-05-25 | 2000-07-19 | Novartis Ag | Organic compounds |
US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
PE20020276A1 (es) * | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
CN1217920C (zh) * | 2000-06-30 | 2005-09-07 | 艾兰制药公司 | 治疗早老性痴呆的化合物 |
US6696488B2 (en) * | 2000-08-11 | 2004-02-24 | The Brigham And Women's Hospital, Inc. | (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production |
WO2002098849A2 (en) * | 2001-06-01 | 2002-12-12 | Elan Pharmaceuticals, Inc. | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases |
BR0211119A (pt) * | 2001-07-11 | 2005-12-13 | Elan Pharm Inc | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto |
AP2004003049A0 (en) * | 2001-11-08 | 2004-06-30 | Elan Pharm Inc | N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives. |
BR0214736A (pt) * | 2001-12-06 | 2004-11-23 | Elan Pharm Inc | Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições |
EA200401114A3 (ru) * | 2002-02-27 | 2005-06-30 | Элан Фармасьютикалз, Инк. | Замещённые гидроксиэтиламины |
CA2481449A1 (en) * | 2002-04-26 | 2003-11-06 | Gilead Sciences, Inc. | Method and compositions for identifying anti-hiv therapeutic compounds |
CA2489988A1 (en) * | 2002-06-20 | 2003-12-31 | Michael R. Reeder | Process for preparing 5-(1,3-oxazol-2-yl) benzoic acid derivatives |
US7557137B2 (en) * | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
US7294642B2 (en) * | 2002-09-06 | 2007-11-13 | Elan Pharmaceuticals, Inc. | 1,3-Diamino-2-hydroxypropane pro-drug derivatives |
UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
DE60329316D1 (de) * | 2002-11-12 | 2009-10-29 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
GB0305918D0 (en) * | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
GB0309221D0 (en) * | 2003-04-23 | 2003-06-04 | Glaxo Group Ltd | Novel compounds |
GB0317491D0 (en) * | 2003-07-25 | 2003-08-27 | Novartis Ag | Organic compounds |
KR100793095B1 (ko) * | 2003-10-01 | 2008-01-10 | 주식회사 프로메디텍 | Bace 저해효능을 가진 신규한 술폰 아미드 유도체 |
GB0323204D0 (en) * | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
US7291744B2 (en) * | 2003-11-13 | 2007-11-06 | Bristol-Myers Squibb Company | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity |
-
2003
- 2003-11-26 US US10/723,220 patent/US7351738B2/en not_active Expired - Fee Related
- 2003-11-26 BR BR0316629-5A patent/BR0316629A/pt not_active IP Right Cessation
- 2003-11-26 PE PE2003001203A patent/PE20040762A1/es not_active Application Discontinuation
- 2003-11-26 MX MXPA05005649A patent/MXPA05005649A/es active IP Right Grant
- 2003-11-26 EP EP03790144A patent/EP1565428A1/en not_active Withdrawn
- 2003-11-26 JP JP2004557383A patent/JP2006508166A/ja active Pending
- 2003-11-26 DO DO2003000765A patent/DOP2003000765A/es unknown
- 2003-11-26 AU AU2003293155A patent/AU2003293155A1/en not_active Abandoned
- 2003-11-26 CA CA002507484A patent/CA2507484A1/en not_active Abandoned
- 2003-11-26 WO PCT/US2003/037998 patent/WO2004050609A1/en active Application Filing
- 2003-11-27 AR ARP030104378A patent/AR043062A1/es not_active Application Discontinuation
- 2003-11-27 TW TW092133639A patent/TW200505828A/zh unknown
- 2003-11-27 PA PA20038589701A patent/PA8589701A1/es unknown
- 2003-11-27 UY UY28101A patent/UY28101A1/es not_active Application Discontinuation
-
2008
- 2008-04-01 US US12/060,544 patent/US20080306136A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR0316629A (pt) | 2005-10-11 |
MXPA05005649A (es) | 2005-08-16 |
US20080306136A1 (en) | 2008-12-11 |
PA8589701A1 (es) | 2004-11-26 |
EP1565428A1 (en) | 2005-08-24 |
AU2003293155A1 (en) | 2004-06-23 |
DOP2003000765A (es) | 2004-05-31 |
PE20040762A1 (es) | 2004-11-06 |
JP2006508166A (ja) | 2006-03-09 |
AR043062A1 (es) | 2005-07-13 |
US7351738B2 (en) | 2008-04-01 |
WO2004050609A1 (en) | 2004-06-17 |
US20040209925A1 (en) | 2004-10-21 |
TW200505828A (en) | 2005-02-16 |
CA2507484A1 (en) | 2004-06-17 |
AU2003293155A8 (en) | 2004-06-23 |
WO2004050609A8 (en) | 2005-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY28101A1 (es) | Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer | |
UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
UY27967A1 (es) | Acetil 2-hindroxi-1,3-diaminoalcanos | |
BR0306724A (pt) | carboxamidas amino substituìdas para tratamento de doença de alzheimer | |
BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
GT200400076A (es) | Ligandos de receptores de cannabinoides y sus usos | |
ATE534736T1 (de) | Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen | |
MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
UY28484A1 (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
DE60210614D1 (de) | Für die behandlung von alzheimer krankheit geeignete makrocyclen | |
MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
BR0314180A (pt) | Aminoéteres substituìdos para o tratamento da doença de alzheimer | |
CR7720A (es) | Acetil 2-hidroxi-1,3- diaminoalcanos | |
MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
MXPA04000337A (es) | Amindioles para tratamiento de enfermedad de alzheimer. | |
UY28458A1 (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos | |
BR0314714A (pt) | Compostos para o tratamento da doença de alzheimer | |
ES2284970T3 (es) | Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer. | |
DOP2004000889A (es) | Fenacilo 2-hidroxi-3-diaminoalcanos (phenacyl 2-hydroxy-3-diaminoalkanes) | |
BR0317445A (pt) | Composto, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto | |
PA8601101A1 (es) | 2-hidroxi-3-diaminoalcanos de benzamida | |
ECSP044940A (es) | N-(3-amino-2-hidroxil-propil) compuestos substitutos de alquilamida | |
GT200500062A (es) | Acetilo 2-hiroxido-1,3 diaminoalcanos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20160120 |